VEGFA and Hypertension: Of these DLTs in cohort 4, there was a grade 3 immune-related myositis / myasthenia gravis (patient ID#019), whereas the second patient (ID#026) developed grade 3 hypertension related to the anti-VEGF activity of sitravatinib that met DLT criteria, as well as grade 3 immune-related pneumonitis at day 64 which rapidly resolved with high dose steroids and therefore did not meet DLT criteria.